Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
18F-FAPI-1007
- Development stage
- Preclinical
- Lead developer
- SOFIE
- Modality
- Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules, Peptides
- Administration
- Intravenous
01
Overview
18F-FAPI-1007 is a radiopharmaceutical used in positron emission tomography (PET) imaging. It is a fluorine-18 labeled fibroblast activation protein inhibitor (FAPI), designed to target the fibroblast activation protein (FAP), which is overexpressed in cancer-associated fibroblasts within the tumor stroma of many epithelial cancers. By binding to FAP, 18F-FAPI-1007 enables high-sensitivity imaging of various tumors and their metastases. The use of fluorine-18 as the radioisotope allows for centralized production and distribution due to its longer half-life compared to gallium-based tracers, making it suitable for wider clinical application. Its mechanism involves specific targeting and visualization of tumor stroma rather than tumor cells themselves, providing valuable information for cancer diagnosis and staging[4].
- Other names
- fluorine-18 labeled fibroblast activation protein inhibitor 1007fluorine18 labeled fibroblast activation protein inhibitor 1007fluorine 18 labeled fibroblast activation protein inhibitor 1007FAPI-1007FAPI1007FAPI 1007[18F]FAPI-1007
02
Targets
FAP (Fibroblast activation protein alpha)
Beyond the preview
Go deeper on 18F-FAPI-1007.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 18F-FAPI-1007.